Concizumab (Anti-TFPI)
Synonyms: NN 7415, mAb 2021, Anti-TFPI Recombinant Antibody
Concizumab (Anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. MW: 145.5 KD.
Mechanism of Action
| Description |
Concizumab (Anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. MW: 145.5 KD.
|
|---|
Product Details
| CAS No. | 1312299-39-0 |
|---|---|
| Molecular Weight | 145.5 kDa |
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
Comparison of Clones for
*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)
Tech Support
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.